Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1100-1107 , September 2009

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation

  • Navneet S. Majhail, MD, MS

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Navneet Majhail, MD, MS, University of Minnesota, Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455.
    • ,
  • Tejo R. Challa, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Daniel A. Mulrooney, MD, MS

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • ,
  • K. Scott Baker, MD, MS

      Affiliations

    • Survivorship Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Linda J. Burns, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota

Received 2 March 2009 ,Accepted 12 May 2009.

References 

  1. Armenian SH, Sun CL, Francisco L. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol. 2008;26:5537–5543
  2. Baker KS, Ness KK, Steinberger J. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood. 2007;109:1765–1772
  3. Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol Oncol. 2004;26:81–90
  4. Majhail NS, Ness KK, Burns LJ. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007;13:1153–1159
  5. Majhail NS, Flowers ME, Ness KK. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43:49–54
  6. Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008;142:11–26
  7. Tichelli A, Bucher C, Rovo A. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463–3471
  8. Tichelli A, Passweg J, Wojcik D. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203–1210
  9. Majhail NS, Brunstein CG, Tomblyn M. Reduced-intensity allogeneic transplantation in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14:282–289
  10. Flynn CM, Hirsch B, Defor T. Reduced-intensity compared with high-dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol. 2007;82:867–872
  11. Brunstein CG, Barker JN, Weisdorf DJ. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064–3070
  12. Arora M, Nagaraj S, Wagner JE. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant. 2007;13:1145–1152
  13. Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  14. Falkner B, Daniels SR. Summary of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Hypertension. 2004;44:387–388
  15. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62–S67
  16. Centers for Disease Control and Prevention: Body mass index. Available from: http://www.cdc.gov/healthyweight/assessing/bmi/index.html. Accessed February 14, 2009.
  17. Nash RA, Antin JH, Karanes C. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–2068
  18. Nash RA, Pineiro LA, Storb R. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88:3634–3641
  19. Ratanatharathorn V, Nash RA, Przepiorka D. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–2314
  20. Hiraoka A, Ohashi Y, Okamoto S. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:181–185
  21. Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl. 2002;S81–S87
  22. Taler SJ, Textor SC, Canzanello VJ. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20:437–449
  23. Textor SC, Taler SJ, Canzanello VJ. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 2000;6:521–530
  24. Taler SJ, Textor SC, Canzanello VJ. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62:1588–1592
  25. Sheean PM, Freels SA, Helton WS. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:656–664
  26. Hammer MJ, Casper C, Gooley TA. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009;15:344–351
  27. Heisel O, Heisel R, Balshaw R. New-onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–595
  28. Moore R, Ravindran V, Baboolal K. The burden of new-onset diabetes mellitus after transplantation. Clin Transplant. 2006;20:755–761
  29. Vincenti F, Friman S, Scheuermann E. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–1514
  30. Hjelmesaeth J, Hartmann A, Kofstad J. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–983
  31. Mathew JT, Rao M, Job V. Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant. 2003;18:164–171
  32. Hjelmesaeth J, Hartmann A, Kofstad J. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant. 2001;16:829–835

 Financial disclosure: See Acknowledgments on page 1106.

PII: S1083-8791(09)00249-3

doi: 10.1016/j.bbmt.2009.05.010

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1100-1107 , September 2009

Article Tools

* Image Usage & Resolution